William J. Olney

William J. Olney

Auto-generated profile, based on publicly available information

William J. Olney

Department of Pharmacy University of Kentucky HealthCare Lexington Kentucky USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2019 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
ANAndrea Newsome
Andrea Newsome
SSSusan E. Smith
Susan E. Smith
WOWilliam J. Olney
William J. Olney
TJTimothy W. Jones
Timothy W. Jones
CFChristy C. Forehand
Christy C. Forehand
LCLindsey Coppiano
Lindsey Coppiano
Background: Clinical pharmacists are established members of the interprofessional patient care team, but limited guidance for the optimal utilization of pharmacy resources is available. Objective measurement of medication regimen complexity offers a novel process for evaluating pharmacist activity. The purpose of this study was to evaluate the relationship between medication regimen complexity, as measured by a novel medication regimen complexity scoring tool (MRC‐ICU), and both pharmacist interventions and drug‐drug interactions (DDIs).Methods: This was a multi‐center, prospective, observational study. The electronic medical record was reviewed to collect patient demographics, patient outcomes, and MRC‐ICU and modified MRC‐ICU (mMRC‐ICU) score at 24, 48 hours, and at discharge. Pharmacist interventions were recorded during the patients' intensive care unit (ICU) stay. DDIs were also evaluated at 24, 48 hours, and at discharge. Spearman's rank‐order correlation was used to determine any correlation between the MRC‐ICU score at each time point and the number of pharmacist interventions and DDIs.Results: A total of 153 patients were evaluated from both centers. The median MRC‐ICU at 24 hours was 11 (interquartile range [IQR] 7‐15). MRC‐ICU at 24 hours was correlated with interventions at 24 hours (rs .439, P <.001). Furthermore, MRC‐ICU was correlated with total DDIs (rs .4, P < .001). A modified version of the MRC‐ICU was also correlated with number of pharmacist interventions (P < .001) and DDIs (P < .001).Conclusions: Medication regimen complexity showed a relationship with number of pharmacist interventions and number of DDIs.

4 February 2021 in Annals of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
TJTimothy W. Jones
Timothy W. Jones
AJAh Hyun Jun
Ah Hyun Jun
JMJessica L. Michal
Jessica L. Michal
WOWilliam J. Olney
William J. Olney
To evaluate evidence for high-dose daptomycin (doses ≥ 8 mg/kg/d). A PubMed/MEDLINE literature search was performed (January 2000 to December 2020) using the search terms daptomycin, high dose, and dosing. Review article references and society guidelines were reviewed. Clinical trials, observational studies, retrospective studies, meta-analyses, and systematic reviews reporting on high-dose daptomycin were included. Experimentally, daptomycin outperforms other antimicrobials for high inoculum and biofilm-associated infections. Clinically, high-dose daptomycin is supported as salvage and first-line therapy for endocarditis and bacteremia, primarily when caused by methicillin-resistant Staphylococcus aureus (when vancomycin minimum inhibitory concentration is >1 mg/L) and Enterococcus. High-dose daptomycin appears effective for osteomyelitis and central nervous system infections, although comparative studies are lacking. High dosing in renal replacement therapy requires considering clearance modality to achieve exposures like normal renal function. Weight-based dosing in obesity draws concern for elevated exposures, although high doses have not been evaluated kinetically in obesity. Some data show benefits of high doses in overweight populations. Burn patients clear daptomycin more rapidly, and high doses may only achieve drug exposures similar to standard doses (6 mg/kg). This review analyzes the efficacy and safety of high-dose daptomycin in serious gram-positive infections. Discussion of specific infectious etiologies and patient populations should encourage clinicians to evaluate their daptomycin dosing standards. The efficacy of high-dose daptomycin and limited safety concerns encourage clinicians to consider high-dose daptomycin more liberally in severe gram-positive infections.

30 July 2024 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
KOKatie B. Olney
Katie B. Olney
MPManjunath Pai
Manjunath Pai
JTJenni K. Thomas
Jenni K. Thomas
DBDonna R. Burgess
Donna R. Burgess
WOWilliam J. Olney
William J. Olney
DBDavid Burgess
David Burgess

15 September 2022 in Journal of Surgical Research
Verified
Journal Article
Closed access
WOWilliam J. Olney
William J. Olney
EJEric G. Johnson
Eric G. Johnson
CPCassidy Potts
Cassidy Potts
JMJ. Thomas Murphy
J. Thomas Murphy
DODouglas R. Oyler
Douglas R. Oyler

14 December 2023 in Critical Care Medicine
Verified
Journal Article
Open access
LHLauren Hochstetler
Lauren Hochstetler
WOWilliam Olney
William Olney
JDJacqueline Dempsey
Jacqueline Dempsey
ZWZachary Warriner
Zachary Warriner
JVJeremy VanHoose
Jeremy VanHoose
SPSara Parli
Sara Parli